Trends & Analysis

#AI / data analytics / healthtech / informatics #Comment #Healthcare #Public health

Expert perspective: 2022 challenges and opportunities

DDW’s Megan Thomas speaks to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector.   Around this time last year, the first Covid-19 vaccines were authorised for emergency use by organisations such as the FDA1, the EMA2, the MHRA3 and many more internationally. Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Biotechnology #Clinical trials #Imaging

Industry predictions for clinical trials 

Medidata reflects on how clinical trials have evolved over the past year, as well as emerging patterns and drivers of change for the coming year. Paul O’Donohoe and Fiona Maini from Medidata explain.  1. The future of clinical trials is decentralised  Decentralised clinical trials, described as the ‘new normal’ in clinical research, harness remote technologies to… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

Human eye
#Clinical trials #Comment #Covid-19 #Eye health

Innovative delivery: sustained ophthalmic steroids in diabetic macular edema 

Listen to this article on the DDW Podcast: Professor Sobha Sivaprasad, Professor of Retinal Clinical Studies, UCL Institute of Ophthalmology, and Consultant Ophthalmologist, Moorfields Eye Hospital, UK discusses unmet needs in DME therapeutics and how they could be addressed by sustained release ophthalmic steroids administered with novel suprachoroidal drug delivery methods.  Diabetic eye… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#AstraZeneca #Biobanking #Genetics #Genomics

Rare variant contribution to human disease  

Listen to this article on the DDW Podcast: Slavé Petrovski and Andrew Harper, Centre for Genomics Research, AstraZeneca, outline the implications and insight offered by the recent publication of an AstraZeneca-authored paper “Rare variant contribution to human disease in 281,104 UK Biobank exomes”.  In August 2021, Nature published the largest and most comprehensive evaluation of the… Read More

#Exclusive Content #News #Opinion #Trends & Analysis

#Comment #Covid-19 #Genetics #Genomics #Public health #Research

Genomics boosts understanding of Covid-19 severity and susceptibility

Listen to this article on the DDW Podcast: The Covid-19 Host Genetics Initiative carried out one of the largest genome-wide association studies ever. It involved meta-analysis of nearly 50,000 Covid-19 patients and two million uninfected controls. Dr Hamdi Mbarek, Lead Analyst of the Qatari dataset explains how the initiative improved knowledge… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Drug discovery #Drug targets #Drug technology #Pharmaceuticals #Quantum computing

How quantum computing can benefit drug discovery 

Listen to this article on the DDW Podcast: Brad Loren, Matthew Marrone, and Christopher Singer, of intellectual property and technology law firm McAndrews, Held & Malloy, on quantum computing and its benefits to drug discovery.  Explaining quantum computing and its promise  Before we explore how QC can benefit drug discovery and drug development,… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Clinical trials #Drug development

Data suggests racial diversity underrepresented in clinical trials 

Phesi has analysed protocol design data and showed that Asian, Hispanic and Latino, Native Americans and Alaska natives, Native Hawaiians and other Pacific Islander patient subpopulations were all significantly and consistently underrepresented over the decade. Black and African American patients appear to have become better represented over the past decade.  The study  The data was… Read More

#News #Trending News #Trends & Analysis

#Biopharma #Biotechnology #Drug innovation #Pharmaceuticals #Report #Research

Pharmaceuticals and biotech lead UK university innovation 

University technology and innovation is driving the UK's status in pharmaceuticals and biotechnology, according to GovGrant’s University Spinouts Report 2021.  The report  According to the new report, the pharmaceuticals and biotechnology sector dominates the top ten spinout companies of the last decade, ranked by valuation. Pharma and biotech companies within the top… Read More

#News #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Chemistry #Drug discovery

Machine learning needs Big Data to revolutionise drug discovery

Machine learning (ML) holds the promise to revolutionise drug discovery. By integrating vast datasets into predictive models, ML will help researchers arrive at the optimal candidate compounds more quickly, disrupting the long cycle times of preclinical discovery research. DEL technology is unmatched in its ability to produce ultra-large datasets. By… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Bioeconomics #Market reporting #Pharmaceuticals

Report: The Latin American research-based pharmaceutical industry  

Examining the role of the pharmaceutical industry in alleviating challenges is helpful to understand how people are benefiting from innovative medicines. This report examines the impact of the pharmaceutical industry in nine Latin American countries (Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, and Peru) by analysing its impact across two dimensions of… Read More

#Market Reports #News #Trends & Analysis

#Covid-19 #Healthcare #Life sciences #Lipids

Evonik eyes Canadian opportunities in Covid-19 fight 

Evonik met with a delegation of representatives from Canada at its site in Darmstadt to discuss competencies in lipid nanoparticles at Evonik’s Vancouver laboratories and evaluate future collaboration opportunities.   Evonik has sites in seven locations in Canada including its Vancouver Laboratories in British Columbia for lipid-based parenteral drug delivery which… Read More

#News #Trending News #Trends & Analysis

#Covid-19 #Immunology / Virology & Vaccines #Measles

Global progress against measles threatened amidst Covid-19 pandemic  

While reported measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to a new report from the World Health Organization (WHO) and US Centers for Disease Control and Prevention (CDC).   During 2020, more than 22… Read More

#News #Trending News #Trends & Analysis

#Biotechnology #Drug development #Inflammatory Bowel Disease #Precision medicine

The start-up changing the game for IBD 

Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut health and IBD in… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone #Trends & Analysis